3 August 2016

Holding(s) in Company

RNS Number : 1048G
Verona Pharma PLC
03 August 2016
 

 

 

 

i

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

 

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

 

 

Verona Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result n the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Other (please specify):

 

 

3. Full name of person(s) subject to the notificatin obligation: iii

 

 

 

Vivo Ventures VI, LLC

 

 

4. Full name of shareholder(s)

(if different from 3.):iv

 

 

Vivo Ventures fund VI, LP

Vivo Ventures VI Affiliates Fund, LP

5. Date of the transaction and date on which the threshold is crossed or

reached: v

 

July 29, 2016

 

6. Date on which issuer notified:

 

July 29, 2016

7. Threshold(s) that is/are crossed or reached:vi,vii

 

1.62% to 2.46% Change at Combined Interest Level

       

 

  8. Notified details:                                                                                                                                            

A: Voting rights attached to shares viii, ix

Class/type of shares

 

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of

Shares

Number of

Voting Rights

Number of shares

Number of oting rights

% of  voting rights x

 

Direct

 

Direct xi

 

Indirect xii

 

Direct

 

Indirect

 

 

 

GB00B06GSH43

 

 

16,400,000

 

 

16,400,000

 

 

63,098,468

 

 

63,098,468

 

 

2.46%

 

 

B: Qualifying Financial Instruments

 

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of oting rights that may be

acquired if the instrument is

exercised/ converted.

% of voting rights

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

xv, xvi

 

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion

period xviii

Number of voting rights instrument refers to

% of voting rights xix,

xx

 

Nominal

 

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

63,098,468

 

2.46%

 

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

 

Vivo Ventures VI, LLC is the general partner of both Vivo Ventures Fund VI, LP (VV Fund VI) and Vivo Ventures VI Affiliates Fund, LP. (Affiliates Fund VI). Accordingly, Vivo Ventures VI,  LLC may be deemed to have indirect beneficial ownership of shares of the Issuer directly owned by VV Fund VI and Affiliates Fund VI. As of the date of this filing, VV Fund VI and Affiliates

Fund VI beneficially own 62,639,570 and 458,898 shares of Common respectively.

 

 

 

 

 

 

  Proxy Voting:                                                                                                                                                    

 

10. Name of the proxy holder:

 

See Section 4

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

 

 

13. Additional information:

 

14. Contact name:

Vivo Capital, LLC Attn: Cinthia Sheu

 

15. Contact telephone number:

 

+1-650-688-0818

 

 

 

 

 

Note: Annex should only be submitted to the FCA not the issuer

 

Annex: Notification of major interests in sharesxxii

 

 

 

 

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Vivo Ventures VI, LLC

Contact address

(registered office for legal entities)

 

575 High Street, suite 201, Palo Alto, CA 94301

Phone number & email

 

650-688-0818; acha@vivocapital.net

Other useful information

(at least legal representative for legal persons)

 

Albert Cha, Managing Member

 

 

 

B: Identity of the notifier, if applicable

Full name

 

Albert Cha

Contact address

 

575 High Street, suite 201, Palo Alto, CA 94301

Phone number & email

 

650-688-0818; acha@vivocapital.net

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligatin)

 

Albert Cha, Managing Member

 

C: Additional information

 

 

 

 

 

 

 

 

For notes on how to complete form TR-1 please see the FCA website.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUUWRUPQUMW

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us